We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
+47.15%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$876M
AUM Growth
+$142M
(+19%)
Cap. Flow
-$21.2M
Cap. Flow
% of AUM
-2.42%
Top 10 Holdings %
Top 10 Hldgs %
56.33%
Holding
39
New
2
Increased
1
Reduced
4
Closed
2
Avg Time Held
1.5
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$21.1M |
| 2 |
Dyne Therapeutics
DYN
|
+$12.3M |
| 3 |
Enliven Therapeutics
ELVN
|
+$9.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mineralys Therapeutics
MLYS
|
+$39.2M |
| 2 |
Compass Pathways
CMPS
|
+$11M |
| 3 |
Soleno Therapeutics
SLNO
|
+$6.64M |
| 4 |
Kura Oncology
KURA
|
+$4.22M |
| 5 |
Third Harmonic Bio
THRD
|
+$2.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Enliven Therapeutics
ELVN
$2.77B
| $9.99M | 1.14% |
+498,000
| New | +$9.43M |
2025 Q2
0 quarters
|
|
27
MBX Biosciences
MBX
$2.41B
| $7.42M | 0.85% |
650,000
| – | – |
2024 Q3
3 quarters
|
|
28
Nektar Therapeutics
NKTR
$1.24B
| $6.89M | 0.79% |
266,666
-1
| -0% | -$11 |
2024 Q1
5 quarters
|
|
29
VistaGen Therapeutics
VTGN
$9.06M
| $5.35M | 0.61% |
2,676,580
| – | – |
2023 Q4
6 quarters
|
|
30
Kodiak Sciences
KOD
$5.55B
| $4.27M | 0.49% |
1,145,538
| – | – |
2023 Q4
6 quarters
|
|
|
31
Kura Oncology
KURA
$842M
| $4.24M | 0.48% |
735,184
-688,458
| -48% | -$4.22M |
2022 Q1
13 quarters
|
|
32
Entrada Therapeutics
TRDA
$185M
| $3.93M | 0.45% |
584,955
| – | – |
2021 Q4
14 quarters
|
|
33
DELISTED
Adverum Biotechnologies
ADVM
| $3.86M | 0.44% |
1,796,482
| – | – |
2024 Q1
5 quarters
|
|
34
Avalo Therapeutics
AVTX
$618M
| $2.41M | 0.28% |
483,000
| – | – |
2024 Q3
3 quarters
|
|
35
DELISTED
Ventyx Biosciences
VTYX
| $677K | 0.08% |
316,195
| – | – |
2022 Q4
10 quarters
|
|
36
Jade Biosciences
JBIO
$852M
| $640K | 0.07% |
64,023
| – | – |
2021 Q4
14 quarters
|
|
37
Cabaletta Bio
CABA
$251M
| $132K | 0.02% |
86,795
| – | – |
2022 Q4
10 quarters
|
|
|
38
Compass Pathways
CMPS
$1.55B
| – | – |
-3,858,000
| Closed | -$11M | – |
|
|
39
Mineralys Therapeutics
MLYS
$1.85B
| – | – |
-2,470,265
| Closed | -$39.2M | – |
|
Similar funds
TCG Crossover Management's Q2 2025 Portfolio in Review
As of Q2 2025, TCG Crossover Management held 39 positions worth $876M, up 19% from $733M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
TCG Crossover Management's Q2 2025 filing shows 2 new, 1 increased, 4 reduced and 2 closed positions. Its largest new stake was Agios Pharmaceuticals: 697,003 shares worth $23.2M. The largest sale was Mineralys Therapeutics, an estimated $39.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- TCG Crossover Management's largest Q2 2025 buy was Agios Pharmaceuticals: 697,003 shares worth $23.2M.
- TCG Crossover Management added most to Dyne Therapeutics in Q2 2025, an estimated $12.3M increase.
- TCG Crossover Management's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $6.64M.
- TCG Crossover Management fully exited Mineralys Therapeutics in Q2 2025, selling an estimated $39.2M.
- TCG Crossover Management's ten largest holdings make up 56% of its $876M portfolio in Q2 2025.
- TCG Crossover Management opened 2 new positions and closed 2 in Q2 2025.
- TCG Crossover Management's portfolio value rose 19% quarter-over-quarter to $876M.
Based on TCG Crossover Management's 13F filing for Q2 2025, filed 14 Aug 2025.